2. Signaling Pathways
  3. Epigenetics
  4. Small Interfering RNA (siRNA)

Small Interfering RNA (siRNA)

Small Interfering RNA (siRNA) is a small exogenous double-stranded RNA (dsRNA) (20-25 nucleotides), which triggers the RNA interference (RNAi) pathway. The short dsRNA unwinds and the sense strand is degraded. Antisense strand forms RNA induced silencing complex (RISC) with various protein components. The antisense strand retained in RISC is specifically complementary to the target gene mRNA. Meanwhile, RISC has nuclease activity, which can cut and degrade the target gene mRNA, and inhibit the expression of target gene. Incomplete complementarity results in mRNA translation inhibition.

Small Interfering RNA (siRNA) Related Products (16303):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-132591
    Inclisiran
    Inclisiran (ALN-PCSsc) is a double-stranded small interfering RNA (siRNA) molecule that inhibits the transcription of PCSK9. Inclisiran can be used for hyperlipidemia and cardiovascular disease (CVD) research.
    Inclisiran
  • HY-132591A
    Inclisiran sodium
    		98.10%
    Inclisiran sodium is a double-stranded small interfering RNA (siRNA) molecule that inhibits the transcription of PCSK9. Inclisiran sodium can be used for hyperlipidemia and cardiovascular disease (CVD) research.
    Inclisiran sodium
  • HY-132610
    Givosiran
    Givosiran (ALN-AS1) is a small interfering RNA that targets hepatic aminolevulinate synthase 1 (ALAS1) messenger RNA. Givosiran downregulates ALAS1 mRNA and prevents accumulation of neurotoxic δ-aminolevulinic acid and porphobilinogen levels. Givosiran can be used for the research of acute intermittent porphyria.
    Givosiran
  • HY-132609
    Patisiran sodium
    Patisiran sodium is a double-stranded small interfering RNA that targets a sequence within the transthyretin (TTR) messenger RNA. Patisiran sodium specifically inhibits hepatic synthesis of mutant and wild-type TTR. Patisiran sodium can be used for the research of hereditary TTR amyloidosis.
    Patisiran sodium
  • HY-150150
    SiRNA Negative Control
    SiRNA Negative Control is a siRNA of 21 nucleotides, and can be used as a negative control.
    SiRNA Negative Control
  • HY-132610A
    Givosiran sodium
    		98.71%
    Givosiran sodium is a small interfering RNA that targets hepatic aminolevulinate synthase 1 (ALAS1) messenger RNA. Givosiran sodium downregulates ALAS1 mRNA and prevents accumulation of neurotoxic δ-aminolevulinic acid and porphobilinogen levels. Givosiran sodium can be used for the research of acute intermittent porphyria.
    Givosiran sodium
  • HY-RS13334
    SLC7A7 Human Pre-designed siRNA Set A
    		Pre-designed Sets

    SLC7A7 Human Pre-designed siRNA Set A contains three designed siRNAs for SLC7A7 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    SLC7A7 Human Pre-designed siRNA Set A
    SLC7A7 Human Pre-designed siRNA Set A
  • HY-RS08166
    MAT1A Human Pre-designed siRNA Set A
    		Pre-designed Sets

    MAT1A Human Pre-designed siRNA Set A contains three designed siRNAs for MAT1A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    MAT1A Human Pre-designed siRNA Set A
    MAT1A Human Pre-designed siRNA Set A
  • HY-132588
    Lumasiran
    Lumasiran (ALN-G01), a siRNA product, reduces hepatic oxalate production by targeting glycolate oxidase. By silencing the gene encoding glycolate oxidase, Lumasiran depletes glycolate oxidase and thereby inhibits the synthesis of oxalate, which is the toxic metabolite that is directly associated with the clinical manifestations of Primary hyperoxaluria type 1 (PH1).
    Lumasiran
  • HY-145720
    Cemdisiran
    Cemdisiran is an N-acetylgalactosamine (GalNAc) conjugated siRNA for the research of complement-mediated diseases by suppressing liver production of complement 5 (C5) protein.
    Cemdisiran
  • HY-132589
    Vutrisiran
    Vutrisiran (ALN-TTRsc02) is a liver-directed, investigational, small interfering ribonucleic acid (siRNA) agent. Vutrisiran can be used for transthyretin (TTR)-mediated amyloidosis research.
    Vutrisiran
  • HY-147425A
    Zerlasiran sodium
    		Inhibitor
    Zerlasiran sodium is an apolipoprotein A (ApoA) synthesis reducer.
    Zerlasiran sodium
  • HY-RS13702
    SPP1 Human Pre-designed siRNA Set A
    		Pre-designed Sets

    SPP1 Human Pre-designed siRNA Set A contains three designed siRNAs for SPP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    SPP1 Human Pre-designed siRNA Set A
    SPP1 Human Pre-designed siRNA Set A
  • HY-150223
    GalNAc unconjugated/naked Inclisiran
    GalNAc unconjugated/naked Inclisiran is a double-stranded small interfering RNA (siRNA) without GalNAc conjugation. GalNAc unconjugated/naked Inclisiran inhibits the transcription of PCSK-9, and can be used for hyperlipidemia and cardiovascular disease (CVD) research.
    GalNAc unconjugated/naked Inclisiran
  • HY-132587
    Fitusiran
    Fitusiran (ALN-AT3SC), an small interfering RNA, specifically targets antithrombin (AT) messenger RNA to lower production of AT in the liver. Fitusiran increases thrombin generation and has the potential for the research of the hemophilia.
    Fitusiran
  • HY-132589A
    Vutrisiran sodium
    Vutrisiran sodium is a liver-directed, investigational, small interfering ribonucleic acid (siRNA) agent. Vutrisiran sodium can be used for transthyretin (TTR)-mediated amyloidosis research.
    Vutrisiran sodium
  • HY-RS16219
    SPP1 Mouse Pre-designed siRNA Set A
    		Pre-designed Sets

    SPP1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for SPP1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    SPP1 Mouse Pre-designed siRNA Set A
    SPP1 Mouse Pre-designed siRNA Set A
  • HY-132613
    Lumasiran sodium
    Lumasiran sodium, an investigational RNA interference (RNAi) therapeutic agent, reduces hepatic oxalate production by targeting glycolate oxidase. Lumasiran sodium reduces urinary oxalate excretion, the cause of progressive kidney failure in primary hyperoxaluria type 1 (PH1) .
    Lumasiran sodium
  • HY-147266
    Elebsiran sodium
    Elebsiran sodium is a siRNA against hepatitis B and D virus infections .
    Elebsiran sodium
  • HY-RS06168
    HIF1A Human Pre-designed siRNA Set A
    		Pre-designed Sets

    HIF1A Human Pre-designed siRNA Set A contains three designed siRNAs for HIF1A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    HIF1A Human Pre-designed siRNA Set A
    HIF1A Human Pre-designed siRNA Set A